# Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

> **NCT00357500** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 101 (actual)

## Conditions studied

- Central Nervous System Tumor, Pediatric
- Leukemia
- Lymphoma
- Neuroblastoma
- Sarcoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** celecoxib
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** fenofibrate
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00357500
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2013-02
- **Final completion:** 2013-12
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2014-10-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357500, "Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00357500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*